Tag Archives: Conversations with Goethe: In the Last Years of His Life by Johann Peter

The New York Review Of Books – June 22, 2023

Image

The New York Review of Books – June 22, 2023 issue: Fara Dabhoiwala on the ingenious index, Ingrid D. Rowland on Guido Reni’s questing soul, Rachel Donadio on Nathalie Sarraute’s sensual eviscerations, Steve Coll on the Taliban’s second emirate, Jessica Riskin on the poisoning of Jane Stanford, Ruth Franklin on Ken Burns’s The US and the Holocaust, Gary Saul Morson on Tolstoy’s conversion, Ed Vulliamy on the Native Americans of California, Linda Greenhouse on judging the Rosenbergs, Gregory Hays on our feline friends, poems by Shane McCrae and Fernando Pessoa, and much more.

Life Is Short. Indexes Are Necessary.

By Fara Dabhoiwala

Index, A History of the: A Bookish Adventure from Medieval Manuscripts to the Digital Age by Dennis Duncan

In his new history of the index, Dennis Duncan traces its evolution through the constantly changing character of reading itself.

In 1941 an ambitious Philadelphia pediatrician, the wonderfully named Waldo Emerson Nelson, became the editor of America’s leading textbook of pediatrics. For the next half-century the compilation of successive editions of this large volume advanced his career, consumed his weekends, and encroached heavily on his domestic life. 

Who Are the Taliban Now?

By Steve Coll

Taliban members walking past a mural on the former US embassy, Kabul

The Return of the Taliban: Afghanistan After the Americans Left by Hassan Abbas

Hassan Abbas’s book surveys the second Islamic Emirate’s ideology and leading personalities and probes its internal tensions.

Nearly two years after the Taliban’s return to power in Kabul, the UN refers to the regime only as “the de facto authorities,” to avoid any hint of formal recognition of the Islamic Emirate of Afghanistan, as the Taliban call their government. By any name, the Taliban today control Afghanistan’s territory, as well as federal ministries and local administrations. They also preside over a nation in severe crisis. Food insecurity haunts at least half of the population; a country shattered by more than four decades of war again faces the shadow of famine.

The New York Review Of Books – May 25, 2023

Image

The New York Review of Books – May 25, 2023 issue: Michael Hofmann on Goethe’s last years, Jerome Groopman on the business of biotech, Joan Acocella on Balanchine, Jed S. Rakoff on William O. Douglas’s environmentalism, Adam Hochschild on 1619 and 1776, Willa Glickman on grassroots labor unions, Brenda Wineapple on Susanna Moore, Ian Johnson on art looters, Jenny Uglow on Samuel Pepys and the wreck of the HMS Gloucester, Nicholas Guyatt on financing the Civil War, Elaine Blair on how we talk about sexual assault, poems by Eugene Ostashevsky, D. Nurske, and Ama Codjoe, and much more.

Bewitched by Goethe

In Johann Eckermann, Goethe found an amanuensis made in heaven.

Conversations with Goethe: In the Last Years of His Life by Johann Peter Eckermann, translated from the German by Allan Blunden, with an introduction and notes by Ritchie Robertson

A strange time to publish—strange time to publish anything—a translation of Eckermann’s  Conversations with Goethe (or should that be Goethe’s Conversations with Eckermann?), in six hundred static, major-key pages that can easily feel like twice as many. The big man, himself by now somewhat fallen on hard times, recorded by the little acolyte.

Saving Lives and Making a Killing

A new book reveals the split personality of the biotech industry: an altruistic enterprise that creates breakthrough treatments for patients in need, and a bare-knuckle business that seeks to generate astronomic profits and stop competitors from developing better treatments.

For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug by Nathan Vardi

A research scientist for Pharmacyclics working in a lab, Sunnyvale, California

A research scientist for Pharmacyclics, Sunnyvale, California, 2013. In For Blood and Money, Nathan Vardi writes that when Pharmacyclics—which developed ibrutinib, a treatment for chronic lymphocytic leukemia—was bought by the pharmaceutical giant AbbVie in 2015 for $21 billion, ‘the deal…set the new high-water mark for success in the biotechnology industry.’